| Hazard Information | Back Directory | [Uses]
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells[1]. | [in vivo]
Inbakicept (0.2 mg/kg; i.v.; twice weekly, for 2 weeks) enhances rituximab-directed protection from a lethal Daudi lymphoma challenge in mouse model[1].
| Animal Model: | SCID mice with Daudi models[1] | | Dosage: | 0.02 mg/kg, 0.05 mg/kg, 0.1 mg/kg, and 0.2 mg/kg | | Administration: | Intravenous injection; twice weekly, for 2 weeks | | Result: | Enhanced rituximab-directed control of Raji lymphoma challenge. |
| [IC 50]
IL-15Rα | [References]
[1] Rosario M, et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016 Feb 1;22(3):596-608. DOI:10.1158/1078-0432.CCR-15-1419 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|